<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255979</url>
  </required_header>
  <id_info>
    <org_study_id>HY209-IV</org_study_id>
    <nct_id>NCT04255979</nct_id>
  </id_info>
  <brief_title>A Study of HY209 in Healthy Male Volunteers for Sepsis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Single Dosing, Dose Escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics of HY209 After Intravenous Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaperon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaperon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled single dosing, dose escalation phase I
      clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 after
      intravenous administration in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HY209, which is being developed for the treatment of sepsis, inhibits inflammation by
      promoting the differentiation and division of Myeloid-derived suppressor cells (MDSCs).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled single dosing, dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of HY209</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Maximum concentration of HY209 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of area under curve infinity (AUCinf) of HY209</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Area under the plasma HY209 concentration-time curve over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of area under curve last (AUClast) of HY209</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Area under the plasma HY209 concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax) of HY209</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Time of maximum concentration of HY209 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal halif-life (t1/2) of HY209</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Terminal half-life of HY209 in plasma</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of HY209 0.1 mg/kg or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of HY209 0.2 mg/kg or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of HY209 0.4 mg/kg or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of HY209 0.8 mg/kg or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of HY209 1.6 mg/kg or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of HY209 3.2 mg/kg or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HY209</intervention_name>
    <description>6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>HY209-IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male aged from 19 to 45 at screening test

          -  BMI 18 kg/m2 ~ 27 kg/m2 at screening test

          -  Subjects found to be clinically healthy by medical history, physical examination,
             vital signs, electrocardiogram (ECG), and appropriate laboratory tests

          -  Those who must be capable of giving informed consent and willing to comply with all
             clinic visits and study-related procedures for the duration of study until study
             completion

        Exclusion Criteria:

          -  Those who have a history of hypersensitivity or clinically significant
             hypersensitivity reactions to drugs (containing Taurodeoxycholate component, aspirin,
             antibiotics, etc.)

          -  Those who showed clinical symptoms suspected of acute infectious disease within 2
             weeks before the first does, or whose body temperature (ear canal) measured at
             screening showed 38 â„ƒ or higher

          -  Those who have a clinically significant disease of liver, kidney, digestive,
             respiratory, endocrine, neurologic, blood/tumor, cardiovascular system history of
             those diseases

          -  Those who have a history of gastrointestinal diseases or surgery that may affect the
             absorption of the investigational drug

          -  Those who have a history of substance abuse or have tested positive for drugs of
             concern for misuse by urine drug screening

          -  Patients with the following blood pressure measured at the seat after resting for more
             than 5 minutes at the screening visit [Systolic blood pressure (SBP): &lt; 90 mmHg or &gt;
             150 mmHg, Diastolic blood pressure (DBP): &lt; 50 mmHg or &gt; 90 mmHg]

          -  Those who participated in other clinical trials or bioequivalence within 6 months
             prior to the first dosing and received the drug

          -  Those who have donated whole blood within 2 months before the first dose or ingredient
             donation within 1 month or received blood transfusion within 1 month

          -  Those who have taken metabolic enzyme-induced and inhibitory drugs within 1 month
             before screening

          -  Those who consumed grapefruit / caffeine-containing foods within 3 days of the first
             dose and who cannot refrain from eating grapefruit-containing foods from 3 days before
             admission to discharge date

          -  Those who have taken specialty or herbal medicines within 2 weeks of the first dose or
             who have taken over-the-counter (OTC) within 1 week

          -  Caffeine overdose, alcohol overdose or oversmoker

          -  Those who have unusual eating habits or who are unable to eat the meals provided in
             this clinical trial

          -  Other investigator judged to be unsuitable as clinical subject
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-jin Jang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inseung Jeon</last_name>
    <phone>82-2-2072-1920</phone>
    <email>isjeon0127@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inseung Jeon</last_name>
      <phone>82-2-2072-1920</phone>
      <email>isjeon0127@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-jin Jang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

